<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331769</url>
  </required_header>
  <id_info>
    <org_study_id>5019</org_study_id>
    <nct_id>NCT04331769</nct_id>
  </id_info>
  <brief_title>CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy</brief_title>
  <acronym>CorCinch-HF</acronym>
  <official_title>Randomized Clinical Evaluation of the AccuCinch® Ventricular Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy: The CORCINCH-HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open-label, international, multi-center clinical study to
      valuate the safety and efficacy of the AccuCinch Ventricular Repair System in patients with
      heart failure and reduced ejection fraction (HFrEF).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2021</start_date>
  <completion_date type="Anticipated">March 27, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device-related major adverse events (MAE)</measure>
    <time_frame>180 days</time_frame>
    <description>MAE defined as:
All-cause death,
Myocardial infarction,
Stroke,
Need for non-elective cardiovascular surgery,
Worsening of heart-failure requiring mechanical circulatory support for more than 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire Quality of Life Questionnaire (KCCQ) Score</measure>
    <time_frame>180 days</time_frame>
    <description>Change in KCCQ Score from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-Minute Walk Test (6MWT) distance (m)</measure>
    <time_frame>180 days</time_frame>
    <description>Change in 6MWT distance (m) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from device-related major adverse events (MAE)</measure>
    <time_frame>365 days</time_frame>
    <description>MAE defined as:
All-cause death,
Myocardial infarction,
Stroke,
Need for non-elective cardiovascular surgery,
Worsening of heart-failure requiring mechanical circulatory support for more than 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A hierarchical composite endpoint, evaluated using the Finkelstein-Shoenfeld Rank Test method:</measure>
    <time_frame>365 days</time_frame>
    <description>Composite defined as:
All-cause death,
LVAD implant or heart transplant,
Number of heart failure hospitalizations, and
Change from baseline KCCQ score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction (HFrEF)</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Device group: AccuCinch Ventricular Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive the AccuCinch Ventricular Repair System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: Guideline-Directed Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive guideline-directed medical therapy (GDMT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AccuCinch Ventricular Repair System</intervention_name>
    <description>AccuCinch Ventricular Repair System</description>
    <arm_group_label>Device group: AccuCinch Ventricular Repair System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guideline-Directed Medical Therapy</intervention_name>
    <description>Guideline-Directed Medical Therapy</description>
    <arm_group_label>Control group: Guideline-Directed Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-years or older

          -  Ejection Fraction: ≥20% and ≤40%

          -  LV end-diastolic diameter ≥55 mm

          -  Symptom Status:

               1. NYHA III,

               2. NYHA ambulatory IV, or

               3. NYHA II with a heart failure hospitalization within the prior 12 months (of
                  signing the consent)

          -  Treatment with guideline-directed medical and device-based therapies for heart failure
             for at least 3 months with medical therapy doses stable for 1 month, stable being
             defined as no more than 100% increase or 50% decrease of total daily doses.
             Device-based therapies defined as:

               1. Patients with left bundle branch block pattern and QRS duration &gt;150ms are
                  required to have a CRT device for at least 3 months, unless otherwise not
                  indicated, prior to randomization

               2. Patients required to have an ICD are required to have ICD implant at least 1
                  month prior to randomization

          -  Able and willing to complete all qualifying diagnostic and functional tests and agrees
             to comply with study follow-up schedule

        Exclusion Criteria:

        Cardiovascular

          1. Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular
             surgery, or carotid surgery within 3 months

          2. Untreated clinically significant coronary artery disease (CAD) requiring
             revascularization

          3. Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile
             aortic atheroma, intracardiac mass, thrombus or vegetation

          4. Wall thickness at the implantation zone &lt;4 mm over a continuous section &gt;10 mm in
             length, measured by contrast CT at end diastole. Implantation zone is defined as the
             basal free wall 5 - 20 mm below the MV plane

          5. Aberrant left ventricular morphology

          6. Hypertrophic cardiomyopathy, amyloid cardiomyopathy, restrictive cardiomyopathy,
             constrictive pericarditis, or any other structural heart disease causing heart failure
             other than dilated cardiomyopathy of either ischemic or non-ischemic etiology

          7. Hemodynamic instability within 30 days defined as, hypotension requiring inotropic
             support or mechanical hemodynamic support

          8. Any planned cardiac surgery or interventions within the next 6 months (including right
             heart procedures)

          9. Active bacterial endocarditis

         10. Severe RV dysfunction

         11. Fixed pulmonary hypertension with PA systolic pressure &gt;70 mmHg not responsive to
             vasodilator therapy

         12. History of any stroke within the prior 3 months or documented Modified Rankin Scale ≥
             4 disability from any prior stroke

             Valvular

         13. Mitral regurgitation grade 3+ (moderate-severe) or 4+ (severe)

         14. Prior mitral or aortic valve replacement

         15. Severe (≥3+) tricuspid regurgitation

         16. Moderate or severe aortic valve stenosis (AVA less than 1.5 cm2 or outflow velocity
             &gt;300 cm/sec)

         17. Aortic regurgitation ≥2+

             Procedural

         18. Anatomical pathology or constraints preventing appropriate access/implant of the
             AccuCinch Ventricular Repair System (e.g., femoral arteries will not support a 20F
             system)

         19. Renal insufficiency (i.e., eGFR of &lt;25ml/min/1.73m2)

         20. Subjects in whom anticoagulation during the procedure is contraindicated

         21. Subjects in whom 90 days of antiplatelet therapy is contraindicated

         22. Known allergy to nitinol, polyester, or polyethylene

         23. Any prior true anaphylactic reaction to contrast agents; defined as known
             anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that
             cannot be adequately pre-medicated prior to the index procedure

             General

         24. Life expectancy &lt;1 year due to non-cardiac conditions

         25. Currently participating in another interventional investigational study

         26. Subjects on high dose steroids or immunosuppressant therapy

         27. Female subjects who are pregnant, of child-bearing potential without a documented
             birth control method, or who are lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

